KR20020011994A - 개선된 약제학적 제형 - Google Patents
개선된 약제학적 제형 Download PDFInfo
- Publication number
- KR20020011994A KR20020011994A KR1020017015577A KR20017015577A KR20020011994A KR 20020011994 A KR20020011994 A KR 20020011994A KR 1020017015577 A KR1020017015577 A KR 1020017015577A KR 20017015577 A KR20017015577 A KR 20017015577A KR 20020011994 A KR20020011994 A KR 20020011994A
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- weight
- ritonavir
- hydroxy
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
성분 | T-1 | T-2 | ||
mg/g | mg/cap | mg/g | mg/cap | |
리토나비어무수 알콜, USP올레산, NF폴리옥시 35 피마자유(Cremophor ELR)BHT | 200.0100.0650.050.00.01 | 200.0100.0650.050.00.01 | 200.0100.0600.0100.00.01 | 200.0100.0600.0100.00.01 |
스케일(mg/캡슐) | 이름 | 양(g) |
적량118.02.00.25704.75100.010.060.05.000 | 질소, N.F.에탄올,무수, USP, 200 프루프에탄올,무수, USP, 200 프루프부틸화 하이드록시톨루엔, NF올레산, NF리토나비어물, 정제시킴, USP(증류시킴)폴리옥시 35 피마자유, NF올레산, NF | 적량118.02.00.25704.75100.010.060.05.000 |
Claims (16)
- (a) HIV 프로테아제 억제 화합물 또는 HIV 프로테아제 억제 화합물의 배합물 또는 약제학적으로 허용되는 이의 염,(b) 장쇄 지방산 또는 장쇄 지방산과 에탄올의 혼합물을 포함하는 약제학적으로 허용되는 유기 용매,(c) 물 및(d) 임의로 약제학적으로 허용되는 표면활성제를 포함하는, 용액으로서의 약제학적 조성물.
- 제1항에 있어서, HIV 프로테아제 억제 화합물이 (2S,3S,5S)-5-(N-(N-((N-메틸-N-((2-이소프로필-4-티아졸릴)메틸)아미노)카보닐)아미노-1,6-디페닐-3-하이드록시헥산(리토나비어; ritonavir)인 조성물.
- 제1항에 있어서, HIV 프로테아제 억제 화합물의 배합물이 (2S,3S,5S)-5-(N-(N-((N-메틸-N-((2-이소프로필-4-티아졸릴)메틸)아미노)카보닐)아미노-1,6-디페닐-3-하이드록시헥산)(리토나비어) 및 (2S,3S,5S)-2-(2,6-디메틸페녹시아세틸)아미노-3-하이드록시-5-[2S-(l-테트라하이드로-피리미드-2-오닐)-3-메틸 부타노일]아미노-1,6-디페닐헥산인 조성물.
- 제1항에 있어서, HIV 프로테아제 억제 화합물 또는 HIV 프로테아제 억제 화합물의 배합물이(2S,3S,5S)-5-(N-(N-((N-메틸-N-((2-이소프로필-4-티아졸릴)메틸)아미노)카보닐)아미노-1,6-디페닐-3-하이드록시헥산(리토나비어),(2S,3S,5S)-5-(N-(N-((N-메틸-N-((2-이소프로필-4-티아졸릴)메틸)아미노)카보닐)아미노-1,6-디페닐-3-하이드록시헥산(리토나비어) 및 (2S,3S,5S)-2-(2,6-디메틸페녹시아세틸)아미노-3-하이드록시-5-[2S-(l-테트라하이드로-피리미드-2-오닐)-3-메틸 부타노일]아미노-1,6-디페닐헥산,N-(2(R)-하이드록시-1(S)-인다닐)-2(R)-페닐메틸-4(S)-하이드록시-5-(l-(4-(3-(피리딜메틸)-2(S)-N'-(t-부틸카복스아미도)-피페라지닐))-펜탄아미드(인디나비어; indinavir)N-3급-부틸-데카하이드로-2-[2(R)-하이드록시-4-페닐-3(S)-[[N-(2-퀴놀릴카보닐)-L-아스파라기닐]아미노]부틸]-(4aS,8aS)-이소퀴놀린-3(S)-카복스아미드(사퀴나비어; saquinavir),5(S)-Boc-아미노-4(S)-하이드록시-6-페닐-2(R)-페닐메틸헥사노일-(L)-Val-(L)-Phe-모르폴린-4-일아미드,1-나프톡시아세틸-베타-메틸티오-Ala-(2S,3S)-3-아미노-2-하이드록시-4-부타노일-1,3-티아졸리딘-4-t-부틸아미드,5-이소퀴놀리녹시아세틸-베타-메틸티오-Ala-(2S,3S)-3-아미노-2-하이드록시-4-부타노일-1,3-티아졸리딘-4-t-부틸아미드,[1S-[1R-(R-),2S*])-Nl[3-[[[(1,1-디메틸에틸)아미노]카보닐](2-메틸프로필)아미노]-2-하이드록시-1-(페닐메틸)프로필]-2-[(2-퀴놀리닐카보닐)아미노]-부탄디아미드,VX-478,DMP-323,DMP-450,AG1343(넬피나비어; nelfinavir),BMS 186,318,SC-55389a,BILA 1096 BS 및U-140690 또는 약제학적으로 허용되는 이의 염으로부터 선택되는 조성물.
- 제1항에 있어서, 장쇄 지방산이 올레산인 조성물.
- 제1항에 있어서, 표면활성제가 폴리옥시 35 피마자유(Cremophor ELR)인 조성물.
- 제1항에 있어서, 용액이 경질 젤라틴 캡슐 또는 연질 젤라틴 캡슐 내에 봉입되어 있는 조성물.
- 제1항에 있어서, 용매가 (1) 전체 용액의 약 40중량% 내지 약 75중량% 양의 약제학적으로 허용되는 장쇄 지방산, (2) 전체 용액의 약 3중량% 내지 약 12중량% 양의 에탄올 및 (3) 전체 용액의 약 0.4중량% 내지 약 1.5중량% 양의 물을 포함하는 조성물.
- 제1항에 있어서, 용매가 (1) 전체 용액의 약 40중량% 내지 75중량%의 양의 올레산, (2) 전체 용액의 약 3중량% 내지 12중량%의 양의 에탄올 및 (3) 전체 용액의 약 0.4중량% 내지 1.5중량%의 양의 물을 포함하는 조성물.
- 제9항에 있어서, HIV 프로테아제 억제 화합물이 (2S,3S,5S)-5-(N-(N-((N-메틸-N-((2-이소프로필-4-티아졸릴)메틸)아미노)카보닐)아미노-1,6-디페닐-3-하이드록시헥산(리토나비어),(2S,3S,5S)-5-(N-(N-((N-메틸-N-((2-이소프로필-4-티아졸릴)메틸)아미노)카보닐)아미노-1,6-디페닐-3-하이드록시헥산(리토나비어) 및 (2S,3S,5S)-2-(2,6-디메틸페녹시아세틸)아미노-3-하이드록시-5-[2S-(l-테트라하이드로-피리미드-2-오닐)-3-메틸 부타노일]아미노-1,6-디페닐헥산,N-(2(R)-하이드록시-1(S)-인다닐)-2(R)-페닐메틸-4(S)-하이드록시-5-(1-(4-(3-피리딜메틸)-2(S)-N'-(t-부틸카복스아미도)-피페라지닐))-펜탄아미드(인디나비어),N-3급-부틸-데카하이드로-2-[2(R)-하이드록시-4-페닐-3(S)-[[N-(2-퀴놀릴카보닐)-L-아스파라기닐]아미노]부틸]-(4aS,8aS)-이소퀴놀린-3(S)-카복스아미드(사퀴나비어),5(S)-Boc-아미노-4(S)-하이드록시-6-페닐-2(R)-페닐메틸헥사노일-(L)-Val-(L)-Phe-모르폴린-4-일아미드,1-나프톡시아세틸-베타-메틸티오-Ala-(2S,3S)-3-아미노-2-하이드록시-4-부타노일 1,3-티아졸리딘-4-t-부틸아미드,5-이소퀴놀린옥시아세틸-베타-메틸티오-Ala-(2S,3S)-3-아미노-2-하이드록시-4-부타노일-1,3-티아졸리딘-4-t-부틸아미드,[1S-[1R-(R-),2S*])-N1[3-[[[(1,1-디메틸에틸)아미노]카보닐](2-메틸프로필)아미노]-2-하이드록시-1-(페닐메틸)프로필]-2-[(2-퀴놀리닐카보닐)아미노]-부탄디아미드,VX-478,DMP-323,DMP-450,AG1343(넬피나비어),BMS 186,318,SC-55389a,BILA 1096 BS 및U-140690 또는 약제학적으로 허용되는 이의 염으로 이루어진 그룹으로부터 선택되는 조성물.
- 제9항에 있어서, HIV 프로테아제 억제 화합물이 리토나비어, (2S,3S,5S)-2-(2,6-디메틸페녹시아세틸)아미노-3-하이드록시-5-(2S-(l-테트라하이드로-피리미드-2-오닐)-3-메틸 부타노일)아미노-1,6-디페닐헥산, 인디나비어, 사퀴나비어, 넬피나비어 또는 VX-478인 조성물.
- 제1항에 있어서, HIV 프로테아제 억제 화합물이 리토나비어 또는 리토나비어와 또 다른 HIV 프로테아제 억제 화합물의 배합물인 조성물.
- 제12항에 있어서, 용액이 연질 탄성 젤라틴 캡슐(SEC) 내에 봉입되어 있는 조성물.
- 제1항에 있어서,(a) 전체 용액의 약 1중량% 내지 약 30중량%의 양의 리토나비어,(b) (1)전체 용액의 약 15중량% 내지 약 99중량%의 양의 올레산 및 (2) 전체 용액의 약 3중량% 내지 약 12중량%의 양의 에탄올을 포함하는 약제학적으로 허용되는 유기 용매,(c) 전체 용액의 약 0.4중량% 내지 약 1.5중량%의 양의 물 및(d) 전체 용액의 약 0중량% 내지 약 20중량%의 양의 폴리옥실 35 피마자유를 포함하는 조성물.
- 제14항에 있어서,(a) 전체 용액의 약 5중량% 내지 약 10중량%의 양의 리토나비어,(b) (1) 전체 용액의 약 70중량% 내지 약 75중량%의 양의 올레산 및 (2) 전체 용액의 약 3중량% 내지 12중량%의 양의 에탄올을 포함하는 약제학적으로 허용되는 유기 용매,(c) 전체 용액의 약 0.4중량% 내지 약 1.5중량%의 양의 물 및(d) 전체 용액의 약 6중량%의 양의 폴리옥실 35 피마자유를 포함하는 조성물.
- 제15항에 있어서, 용액이 연질 탄성 젤라틴 캡슐(SEC) 내에 봉입되어 있는 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32582699A | 1999-06-04 | 1999-06-04 | |
US09/325,826 | 1999-06-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020011994A true KR20020011994A (ko) | 2002-02-09 |
KR100815412B1 KR100815412B1 (ko) | 2008-03-20 |
Family
ID=23269615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017015577A KR100815412B1 (ko) | 1999-06-04 | 2000-05-25 | 개선된 약제학적 제형 |
Country Status (33)
Country | Link |
---|---|
EP (2) | EP1183026B1 (ko) |
JP (1) | JP4753511B2 (ko) |
KR (1) | KR100815412B1 (ko) |
CN (2) | CN100418527C (ko) |
AR (2) | AR032586A1 (ko) |
AT (2) | ATE429224T1 (ko) |
AU (1) | AU778198B2 (ko) |
BG (1) | BG65445B1 (ko) |
BR (1) | BR0007294A (ko) |
CA (1) | CA2371109C (ko) |
CL (1) | CL2008003491A1 (ko) |
CO (1) | CO5160323A1 (ko) |
CY (2) | CY1105237T1 (ko) |
CZ (1) | CZ301308B6 (ko) |
DE (2) | DE60029219T2 (ko) |
DK (2) | DK1733725T4 (ko) |
ES (2) | ES2324549T5 (ko) |
HK (1) | HK1045804A1 (ko) |
HU (1) | HU229501B1 (ko) |
IL (3) | IL146025A0 (ko) |
MX (1) | MXPA01012478A (ko) |
MY (1) | MY127908A (ko) |
NO (1) | NO328968B1 (ko) |
NZ (1) | NZ515016A (ko) |
PL (1) | PL197671B1 (ko) |
PT (2) | PT1733725E (ko) |
SA (1) | SA00210237B1 (ko) |
SI (2) | SI1183026T1 (ko) |
SK (2) | SK287185B6 (ko) |
TR (1) | TR200103488T2 (ko) |
TW (1) | TWI244390B (ko) |
WO (1) | WO2000074677A2 (ko) |
ZA (1) | ZA200108641B (ko) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5090830A1 (es) * | 1998-07-20 | 2001-10-30 | Abbott Lab | Poliformo de un agente farmaceutico |
CA2371109C (en) * | 1999-06-04 | 2011-04-26 | Laman A. Alani | Improved pharmaceutical formulations |
US7141593B1 (en) | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
DE60028754T2 (de) | 1999-11-12 | 2007-05-31 | Abbott Laboratories, Abbott Park | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
ES2304990T3 (es) * | 2000-01-19 | 2008-11-01 | Abbott Laboratories | Formulaciones farmaceuticas de inhibidores de la proteasa del vih mejoradas. |
MXPA03010771A (es) * | 2001-05-25 | 2004-07-01 | Abbott Lab | Capsulas elasticas blandas que comprenden ritonavir y/o lopinavir. |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
SG170795A1 (en) * | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
AU2015258296B2 (en) * | 2006-07-07 | 2017-08-17 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
AU2013204805C1 (en) * | 2006-07-07 | 2017-03-09 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
EP3696171A1 (en) | 2006-07-07 | 2020-08-19 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
NO347119B1 (no) * | 2006-07-07 | 2023-05-15 | Gilead Sciences Inc | Modulatorer av farmakokinetikkegenskaper til terapeutika |
AU2015234299B2 (en) * | 2006-07-07 | 2017-03-09 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
EP2112925A4 (en) | 2006-11-15 | 2013-01-09 | Abbott Lab | SOLID PHARMACEUTICAL DOSAGE FORMULATIONS |
AU2015204378B2 (en) * | 2007-02-23 | 2017-03-09 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
AU2013204817B2 (en) * | 2007-02-23 | 2015-05-07 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
SI2487162T1 (sl) | 2007-02-23 | 2016-12-30 | Gilead Sciences, Inc. | Modulatorji farmakokinetičnih lastnosti terapevtskih sredstev |
EP3150586B1 (en) * | 2007-02-23 | 2020-01-08 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
CN101796040A (zh) | 2007-07-06 | 2010-08-04 | 吉里德科学公司 | 治疗剂的药代动力学特性调节剂 |
PT2231628E (pt) | 2008-01-04 | 2015-12-29 | Gilead Sciences Inc | Inibidores de citocromo p450 |
UA108738C2 (uk) * | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5696270A (en) * | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
IL110752A (en) † | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) * | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
IL111991A (en) † | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
JP4157969B2 (ja) * | 1994-03-18 | 2008-10-01 | スパーナス ファーマシューティカルズ インコーポレイテッド | 乳化薬物送達システム |
DE4431489A1 (de) * | 1994-09-03 | 1996-03-07 | Heidelberger Baustofftech Gmbh | Schnellhärtende aminosilanvernetzende Silikonmassen |
US5567823A (en) * | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
WO1997021683A1 (en) * | 1995-12-13 | 1997-06-19 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
CO5090830A1 (es) * | 1998-07-20 | 2001-10-30 | Abbott Lab | Poliformo de un agente farmaceutico |
CA2371109C (en) * | 1999-06-04 | 2011-04-26 | Laman A. Alani | Improved pharmaceutical formulations |
-
2000
- 2000-05-25 CA CA2371109A patent/CA2371109C/en not_active Expired - Lifetime
- 2000-05-25 NZ NZ515016A patent/NZ515016A/xx not_active IP Right Cessation
- 2000-05-25 DE DE60029219T patent/DE60029219T2/de not_active Expired - Lifetime
- 2000-05-25 CZ CZ20014293A patent/CZ301308B6/cs not_active IP Right Cessation
- 2000-05-25 SK SK5083-2007A patent/SK287185B6/sk not_active IP Right Cessation
- 2000-05-25 ES ES06114684T patent/ES2324549T5/es not_active Expired - Lifetime
- 2000-05-25 DK DK06114684.1T patent/DK1733725T4/da active
- 2000-05-25 CN CNB008083207A patent/CN100418527C/zh not_active Expired - Lifetime
- 2000-05-25 SK SK1720-2001A patent/SK286305B6/sk not_active IP Right Cessation
- 2000-05-25 SI SI200030880T patent/SI1183026T1/sl unknown
- 2000-05-25 PT PT06114684T patent/PT1733725E/pt unknown
- 2000-05-25 IL IL14602500A patent/IL146025A0/xx unknown
- 2000-05-25 KR KR1020017015577A patent/KR100815412B1/ko active IP Right Grant
- 2000-05-25 TR TR2001/03488T patent/TR200103488T2/xx unknown
- 2000-05-25 HU HU0201591A patent/HU229501B1/hu not_active IP Right Cessation
- 2000-05-25 WO PCT/US2000/014342 patent/WO2000074677A2/en active Application Filing
- 2000-05-25 AT AT06114684T patent/ATE429224T1/de active
- 2000-05-25 ES ES00937743T patent/ES2265946T3/es not_active Expired - Lifetime
- 2000-05-25 SI SI200031028T patent/SI1733725T2/sl unknown
- 2000-05-25 PT PT00937743T patent/PT1183026E/pt unknown
- 2000-05-25 CN CN2008101301744A patent/CN101361723B/zh not_active Expired - Lifetime
- 2000-05-25 AT AT00937743T patent/ATE332132T1/de active
- 2000-05-25 JP JP2001501214A patent/JP4753511B2/ja not_active Expired - Lifetime
- 2000-05-25 BR BR0007294-0A patent/BR0007294A/pt not_active Application Discontinuation
- 2000-05-25 EP EP00937743A patent/EP1183026B1/en not_active Expired - Lifetime
- 2000-05-25 EP EP06114684A patent/EP1733725B2/en not_active Expired - Lifetime
- 2000-05-25 AU AU52877/00A patent/AU778198B2/en not_active Revoked
- 2000-05-25 MX MXPA01012478A patent/MXPA01012478A/es active IP Right Grant
- 2000-05-25 DK DK00937743T patent/DK1183026T3/da active
- 2000-05-25 PL PL351943A patent/PL197671B1/pl unknown
- 2000-05-25 DE DE60042092T patent/DE60042092D1/de not_active Expired - Lifetime
- 2000-05-31 MY MYPI20002425A patent/MY127908A/en unknown
- 2000-05-31 CO CO00040645A patent/CO5160323A1/es unknown
- 2000-06-02 AR ARP000102748A patent/AR032586A1/es not_active Application Discontinuation
- 2000-06-03 TW TW089110863A patent/TWI244390B/zh active
- 2000-07-17 SA SA00210237A patent/SA00210237B1/ar unknown
-
2001
- 2001-10-18 IL IL146025A patent/IL146025A/en active IP Right Grant
- 2001-10-19 ZA ZA200108641A patent/ZA200108641B/en unknown
- 2001-11-20 NO NO20015670A patent/NO328968B1/no not_active Application Discontinuation
- 2001-12-19 BG BG106239A patent/BG65445B1/bg unknown
-
2002
- 2002-07-31 HK HK02105647A patent/HK1045804A1/xx not_active IP Right Cessation
-
2006
- 2006-09-21 CY CY20061101354T patent/CY1105237T1/el unknown
-
2007
- 2007-12-12 AR ARP070105573A patent/AR064309A2/es not_active Application Discontinuation
-
2008
- 2008-11-24 CL CL2008003491A patent/CL2008003491A1/es unknown
-
2009
- 2009-06-29 CY CY20091100675T patent/CY1109135T1/el unknown
-
2011
- 2011-11-29 IL IL216686A patent/IL216686A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7981911B2 (en) | Pharmaceutical formulations | |
KR100815412B1 (ko) | 개선된 약제학적 제형 | |
AU2006235895B2 (en) | Improved pharmaceutical formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20130227 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140227 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150227 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161229 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20181227 Year of fee payment: 12 |